Bivictrix quits London’s AIM to chase private funding as market ‘undervalues’ firm

Biotech firm Bivictrix Therapeutics is the latest company to exit the London Stock Exchange’s AIM market, citing difficulties in raising funds compared to its privately-owned competitors. The company, which is headquartered in Macclesfield, said it would not be able to raise enough capital to advance its medication to a clinical trial via London’s junior market [...]